CAMP4 Therapeutics Corporation cash flow to debt ratio of -1.50K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

CAMP4 Therapeutics Corporation's free cash flow has increased -35.15% from $-46.00M last year to $-29.83M, signaling increasing performance

CAMP4 Therapeutics Corporation's debt to equity ratio is 0.07, which means that the company's assets are healthy financed, signaling financial stability.

CAMP4 Therapeutics Corporation's debt has decreased relative to shareholder equity from 0.14 last year to 0.07 today, signaling strengthened financials

CAMP4 Therapeutics Corporation has a net cash position, so leverage is healthy.

CAMP4 Therapeutics Corporation earns at least as much interest as it pays. Interest obligations are fully covered.

CAMP4 Therapeutics Corporation's profit margin has increased (-72.38%) in the last year from -7.94K% to -2.19K%, signaling increasing performance

CAMP4 Therapeutics Corporation's short-term assets of $114.09M exceed its short-term liabilities of $15.51M

CAMP4 Therapeutics Corporation's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

CAMP4 Therapeutics Corporation's return on equity of -194.74%, is lower than 15.00%, indicating bad performance

CAMP4 Therapeutics Corporation's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

CAMP4 Therapeutics Corporation has insufficient public price history to evaluate earnings stability.

CAMP4 Therapeutics Corporation has negative free cash flow, indicating the company is burning cash rather than generating it

CAMP4 Therapeutics Corporation has negative free cash flow, indicating cash burn

CAMP4 Therapeutics Corporation's yearly earnings has decreased 55.25% since last year from $-51.79M to $-80.40M, signaling decreasing performance

CAMP4 Therapeutics Corporation's yearly revenue has increased 436.50% since last year from $652.00K to $3.50M, signaling increasing performance

ROIC -58.32% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

CAMP4 Therapeutics Corporation has insufficient revenue history to calculate 3-year revenue CAGR.

CAMP4 Therapeutics Corporation has insufficient public price history to evaluate revenue consistency.

CAMP4 Therapeutics Corporation has insufficient public price history to evaluate ROE consistency.

CAMP4 Therapeutics Corporation has insufficient data to evaluate this check.

CAMP4 Therapeutics Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

CAMP4 Therapeutics Corporation is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

CAMP4 Therapeutics Corporation has negative or missing EBITDA, making EV/EBITDA ratio unreliable

CAMP4 Therapeutics Corporation has insufficient data to evaluate this check.

CAMP4 Therapeutics Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

CAMP4 Therapeutics Corporation has a price-to-book ratio of 7.91x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

CAMP4 Therapeutics Corporation has a price-to-sales ratio of 62.15x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue